Optin Neuritis. neuropathy, except ischaemic
Conditions
Interventions
Intervention 1: Group Intervention: Memantine tablets 10 mg once daily, for three months. Intervention 2: Control group : placebo Designed by memantine company manufactures with same packaging.
Treatment - Drugs
Placebo
Group Intervention: Memantine tablets 10 mg once daily, for three months.
Control group : placebo Designed by memantine company manufactures with same packaging.
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 46 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: age range 18 to 46 years; the first attack of acute optic neuritis with visual symptoms of 8 days duration or less . Exclusion criteria: lack of diagnostic criteria of multiple sclerosis; negative history of immunosuppressive drugs ; no history of ophthalmic problems or surgery.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Acuity. Timepoint: Start of study, 3 Month after treatment. Method of measurement: Snelen chart. | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Evoked Potential. Timepoint: Start of Study, 3 Month after treatment. Method of measurement: with Visual Evoked Potential instrument. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDina Motamedi
Tehran University of Medical Science
Outcome results
None listed